BRPI0416993A - partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas - Google Patents

partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas

Info

Publication number
BRPI0416993A
BRPI0416993A BRPI0416993-0A BRPI0416993A BRPI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A
Authority
BR
Brazil
Prior art keywords
particle
diagnostic
agent
pharmaceutical
preparation process
Prior art date
Application number
BRPI0416993-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Oskar Axelsson
Ib Leunbach
Magnus Karlsson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20035294A external-priority patent/NO20035294D0/no
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0416993A publication Critical patent/BRPI0416993A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/10—Metallic powder containing lubricating or binding agents; Metallic powder containing organic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BRPI0416993-0A 2003-11-28 2004-11-26 partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas BRPI0416993A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20035294A NO20035294D0 (no) 2003-11-28 2003-11-28 Forbindelser
NO20044622 2004-10-26
PCT/NO2004/000364 WO2005051435A2 (en) 2003-11-28 2004-11-26 Tungsten particles as x-ray contrast agents

Publications (1)

Publication Number Publication Date
BRPI0416993A true BRPI0416993A (pt) 2007-02-06

Family

ID=34635761

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416993-0A BRPI0416993A (pt) 2003-11-28 2004-11-26 partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas

Country Status (10)

Country Link
US (1) US20070031339A1 (https=)
EP (1) EP1694366A2 (https=)
JP (1) JP4974222B2 (https=)
KR (1) KR101128577B1 (https=)
AU (1) AU2004292917A1 (https=)
BR (1) BRPI0416993A (https=)
CA (1) CA2547476A1 (https=)
MX (1) MXPA06006044A (https=)
RU (1) RU2361617C2 (https=)
WO (1) WO2005051435A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20052429D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Konstrastmidler
NO20052428D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Kontrastmidler
US8173166B2 (en) * 2005-09-09 2012-05-08 Honda Motor Co., Ltd. Methods of producing tungsten nanoparticles
US9149545B2 (en) 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
US8003883B2 (en) 2007-01-11 2011-08-23 General Electric Company Nanowall solar cells and optoelectronic devices
US7977568B2 (en) 2007-01-11 2011-07-12 General Electric Company Multilayered film-nanowire composite, bifacial, and tandem solar cells
CN100565156C (zh) * 2007-02-09 2009-12-02 中国钢铁股份有限公司 混凝土结构物的裂缝检测方法
RU2508053C2 (ru) 2008-07-07 2014-02-27 Конинклейке Филипс Электроникс Н.В. Визуализация к-края
EP2376137A2 (en) * 2008-11-23 2011-10-19 Medtronic, Inc. Medical devices with encapsulated visibility particles
WO2013022499A2 (en) * 2011-04-22 2013-02-14 Emory University Polymer coated metal particles and uses related thereto
WO2013034446A1 (en) * 2011-09-07 2013-03-14 Dahan Elodie An apparatus and method for generating useful energy
US9989482B2 (en) * 2016-02-16 2018-06-05 General Electric Company Methods for radiographic and CT inspection of additively manufactured workpieces
US20200179539A1 (en) * 2016-06-22 2020-06-11 Board Of Regents, The University Of Texas System Contrast Agents and Methods of Making the Same for Spectral CT That Exhibit Cloaking and Auto-Segmentation
JP2019128288A (ja) * 2018-01-25 2019-08-01 三井化学株式会社 きずの観察方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181626A (en) * 1977-12-27 1980-01-01 Ppg Industries, Inc. Method of preparing tungsten hexacarbonyl containing polymers and polymers prepared thereby
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
DE69207589T2 (de) * 1992-06-01 1996-05-23 Basf Ag Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln
US5728590A (en) * 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
AU687093B2 (en) * 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
US5759230A (en) * 1995-11-30 1998-06-02 The United States Of America As Represented By The Secretary Of The Navy Nanostructured metallic powders and films via an alcoholic solvent process
JP3411497B2 (ja) * 1998-03-25 2003-06-03 科学技術振興事業団 Ｗ超微粒子とその製造方法、およびｗナノ結晶薄膜
FR2777016B1 (fr) * 1998-04-06 2002-06-14 Rhone Poulenc Agrochimie Silicone azotee utile pour compacter les sequences d'acides nucleiques et utilisation pour la transfection
WO2000028920A1 (en) * 1998-11-13 2000-05-25 Biocompatibles Limited Therapeutic use of polymers
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
RU2173173C2 (ru) * 1999-05-12 2001-09-10 Институт химии твердого тела Уральского Отделения РАН Средство для контрастирования при рентгенодиагностике (варианты) и способ его получения
RU2172990C2 (ru) * 1999-06-01 2001-08-27 Валерий Иванович Печенкин Рентгенопоглощающий материал
CA2401270A1 (en) * 2000-03-10 2001-09-20 Jeff W. Lichtman Method for labeling individual cells
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
ITVI20010126A1 (it) * 2001-05-30 2002-11-30 Tecres Spa Cemento osseo radiopaco per uso ortopedico nonche' metodo di realizzazione
JP2004537551A (ja) 2001-07-20 2004-12-16 イオメド インコーポレイテッド メトトレキサートに基づく薬剤を投与することによって腫瘍性、血管原性、繊維芽細胞性及び／又は免疫抑制性眼球異常を治療する方法及びメトトレキサートに基づく薬剤を送達するための眼球イオン導入装置。
FR2830022B1 (fr) * 2001-09-26 2004-08-27 Cime Bocuze Alliage base tungstene fritte a haute puissance
US6686308B2 (en) * 2001-12-03 2004-02-03 3M Innovative Properties Company Supported nanoparticle catalyst
AU2002351240A1 (en) * 2002-03-08 2003-09-22 James Hainfeld Gold nanoparticles used for x-rays imaging
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization

Also Published As

Publication number Publication date
MXPA06006044A (es) 2006-09-04
RU2006117818A (ru) 2008-01-10
KR101128577B1 (ko) 2012-03-28
RU2361617C2 (ru) 2009-07-20
EP1694366A2 (en) 2006-08-30
AU2004292917A1 (en) 2005-06-09
JP2007512322A (ja) 2007-05-17
WO2005051435A2 (en) 2005-06-09
WO2005051435A3 (en) 2006-07-13
CA2547476A1 (en) 2005-06-09
JP4974222B2 (ja) 2012-07-11
US20070031339A1 (en) 2007-02-08
KR20060118515A (ko) 2006-11-23

Similar Documents

Publication Publication Date Title
BRPI0416993A (pt) partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas
Ibraheem et al. Ciprofloxacin-loaded silver nanoparticles as potent nano-antibiotics against resistant pathogenic bacteria
Moosmann et al. Designer benzodiazepines: a new challenge
López-Galindo et al. Compositional, technical and safety specifications of clays to be used as pharmaceutical and cosmetic products
Li et al. Synthesis and controlled release properties of prednisone intercalated Mg− Al layered double hydroxide composite
Orlowski et al. Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection
Exley Does antiperspirant use increase the risk of aluminium-related disease, including Alzheimer's disease?
Verma et al. Mechanistic insight into size-dependent enhanced cytotoxicity of industrial antibacterial titanium oxide nanoparticles on colon cells because of reactive oxygen species quenching and neutral lipid alteration
FR2755136B1 (fr) Procede de preparation de nanoparticules de methylidene malonate, nanoparticules contenant eventuellement une ou plusieurs molecules biologiquement actives et compositions pharmaceutiques les contenant
Melo et al. The role of nanomaterials in cosmetics: national and international legislative aspects
Pandya et al. Zeolite-based nanoparticles drug delivery systems in modern pharmaceutical research and environmental remediation
BR0111335A (pt) Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
BR0309894A (pt) Composição, processo para preparar uma composição de celulose microcristalina, produto alimentìcio, composição farmacêutica, composição cosmética, forma de dosagem farmacêutica, e, composição industrial
BR0112903A (pt) Pó eletrostático
Pavani et al. Liquisolid technique based sustained release tablet of trimetazidine dihydrochloride
Vlachogianni et al. Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer
Kubala-Drincic et al. Matrix solid-phase dispersion extraction and gas chromatographic determination of chloramphenicol in muscle tissue
Rana et al. Bentonite in Korea: A resource and research focus for biomedical and cosmetic industries
Qasim et al. The effect of chitosan derived silver nanoparticles on mechanical properties, color stability of glass ionomer luting cements
Thakral et al. Quantification, mechanism, and mitigation of active ingredient phase transformation in tablets
Larkin et al. Illuminating the health and safety of luminol
Kleyi et al. Folic Acid–Intercalated Mg/Al Layered Double Hydroxides─ A Multifunctional Nanohybrid Delivery System for Topical Applications
Goyanes et al. Chitosan–kaolin coprecipitate as disintegrant in microcrystalline cellulose-based pellets elaborated by extrusion–spheronization
Godek et al. Influence of zwitterionic CAPB on flocculation of the aqueous cationic guar gum/glauconite suspensions at various pH
HUP0303804A3 (en) Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.